These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 23312237)

  • 41. Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models.
    Gozgit JM; Squillace RM; Wongchenko MJ; Miller D; Wardwell S; Mohemmad Q; Narasimhan NI; Wang F; Clackson T; Rivera VM
    Cancer Chemother Pharmacol; 2013 May; 71(5):1315-23. PubMed ID: 23468082
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
    Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Review of combination therapy with mTOR inhibitors and tacrolimus minimization after transplantation.
    Peddi VR; Wiseman A; Chavin K; Slakey D
    Transplant Rev (Orlando); 2013 Oct; 27(4):97-107. PubMed ID: 23932018
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Oral and intravenously administered mTOR inhibitors for metastatic renal cell carcinoma: pharmacokinetic considerations and clinical implications.
    Danesi R; Boni JP; Ravaud A
    Cancer Treat Rev; 2013 Nov; 39(7):784-92. PubMed ID: 23375248
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe aphthous stomatitis associated with oral calcineurin and mTOR inhibitors.
    Habib N; Salaro C; Al-Ghaithi K; Phelps RG; Saggar S; Cohen SR
    Int J Dermatol; 2010 Jan; 49(1):91-4. PubMed ID: 20465622
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Development of everolimus, a novel oral mTOR inhibitor, across a spectrum of diseases.
    Lebwohl D; Anak O; Sahmoud T; Klimovsky J; Elmroth I; Haas T; Posluszny J; Saletan S; Berg W
    Ann N Y Acad Sci; 2013 Jul; 1291():14-32. PubMed ID: 23659703
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer].
    Katayama K; Yamagishi J; Kashiwagi B
    Gan To Kagaku Ryoho; 2013 Mar; 40(3):365-9. PubMed ID: 23507600
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
    Thompson LA; Kim M; Wenger SD; O'Bryant CL
    Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies.
    Shih T; Lindley C
    Clin Ther; 2006 Nov; 28(11):1779-802. PubMed ID: 17212999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
    Barnett CM
    Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Targeting mTOR pathway in gynecological malignancies: Biological rationale and systematic review of published data.
    Kassem L; Abdel-Rahman O
    Crit Rev Oncol Hematol; 2016 Dec; 108():1-12. PubMed ID: 27931828
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Topical Application of a Galenical Formulation for the Management of Everolimus-Induced Mucositis in Patients with Metastatic Cancer: a Retrospective Study.
    Conforti S; Minardi S; Conforti L; Turano S; Bilotta S; Vilardo E; Palazzo S
    Oncol Ther; 2016; 4(2):275-286. PubMed ID: 28261655
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gastrointestinal toxicities from targeted therapies: measurement, duration and impact.
    Bossi P; Lucchesi M; Antonuzzo A
    Curr Opin Support Palliat Care; 2015 Jun; 9(2):163-7. PubMed ID: 25872123
    [TBL] [Abstract][Full Text] [Related]  

  • 54. mTOR inhibitor-related pulmonary toxicity; incidence even higher.
    Willemsen AE; van Herpen CM
    Acta Oncol; 2013 Aug; 52(6):1234. PubMed ID: 23409770
    [No Abstract]   [Full Text] [Related]  

  • 55. Reply to "mTOR inhibitor-related pulmonary toxicity; incidence even higher".
    Palazzo A; Iacovelli R; Cortesi E
    Acta Oncol; 2013 Aug; 52(6):1235. PubMed ID: 23614779
    [No Abstract]   [Full Text] [Related]  

  • 56. Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.
    Shameem R; Lacouture M; Wu S
    Cancer Invest; 2015 Mar; 33(3):70-7. PubMed ID: 25635371
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Cutaneous adverse effects of targeted therapies: Part II: Inhibitors of intracellular molecular signaling pathways.
    Macdonald JB; Macdonald B; Golitz LE; LoRusso P; Sekulic A
    J Am Acad Dermatol; 2015 Feb; 72(2):221-36; quiz 237-8. PubMed ID: 25592339
    [TBL] [Abstract][Full Text] [Related]  

  • 58. mTOR inhibitor-associated stomatitis (mIAS) in three patients with cancer treated with everolimus.
    Kalogirou EM; Tosios KI; Piperi EP; Sklavounou A
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2015 Jan; 119(1):e13-9. PubMed ID: 25442249
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Stomatitis And Everolimus: A Review Of Current Literature On 8,201 Patients.
    Arena C; Troiano G; Zhurakivska K; Nocini R; Lo Muzio L
    Onco Targets Ther; 2019; 12():9669-9683. PubMed ID: 31814732
    [TBL] [Abstract][Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.